Clinical Trial Details
| Trial ID: | L5362 |
| Source ID: | NCT00979459 |
| Associated Drug: | Mk-1006 Dfc |
| Title: | A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED) |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | YES |
| Results: | https://ClinicalTrials.gov/show/NCT00979459/results |
| Conditions: | Type 2 Diabetes |
| Interventions: | DRUG: MK-1006 DFC|DRUG: MK-1006 FCT |
| Outcome Measures: | Primary: Area Under the Concentration Versus Time Curve (AUC(0-infinity)) for MK-1006, AUC (0-infinity) is the area under the curve for the plot showing plasma concentration against time from time zero to the time of the last quantifiable concentration for two formulations of MK-1006, FCT and DFC, Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96 and 120 hours post-dose|Maximum Plasma Concentration (Cmax) for MK-1006, Maximum plasma concentration for 2 formulations of MK-1006, FCT and DFC, Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96 and 120 hours post-dose | Secondary: Number of Participants Who Experienced at Least One Adverse Event, Through 30 days post-dose|Number of Participants Who Discontinued Study Medication Due to an Adverse Event, up to 8 days |
| Sponsor/Collaborators: | Sponsor: Merck Sharp & Dohme LLC |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE1 |
| Enrollment: | 12 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2009-09 |
| Completion Date: | 2009-12 |
| Results First Posted: | 2012-08-20 |
| Last Update Posted: | 2016-02-05 |
| Locations: | |
| URL: | https://clinicaltrials.gov/show/NCT00979459 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|